Liver Function Test Monitoring for Ofev (Nintedanib)
Check liver function tests (ALT, AST, and bilirubin) prior to starting Ofev, then at regular intervals during the first three months of treatment, and periodically thereafter or as clinically indicated. 111
Specific Monitoring Schedule
Initial Phase (First 3 Months)
- Baseline: Obtain LFTs before initiating treatment
- First 3 months: Monitor at regular intervals (the FDA label specifies "regular intervals" without defining exact frequency, but given the high-risk period, monthly monitoring is standard practice)
- Critical window: The majority of hepatic events occur within the first three months of treatment 11
Maintenance Phase (After 3 Months)
- Periodic monitoring: Continue LFTs periodically after the initial 3-month period
- Symptom-triggered: Check promptly if patients report symptoms suggesting liver injury (fatigue, anorexia, right upper abdominal discomfort, dark urine, or jaundice) 11
High-Risk Populations Requiring Closer Monitoring
Certain patients warrant more intensive surveillance:
- Female patients (3-4 times higher risk of liver enzyme elevations) 2
- Low body weight (<65 kg) 13
- Asian ethnicity 1
- Older age (increased nintedanib exposure) 1
- Pre-existing liver disease 3
- Multiple comorbidities (≥4 comorbidities) 3
- Alcohol consumption 3
What to Monitor
The FDA label specifically requires:
- ALT (alanine aminotransferase)
- AST (aspartate aminotransferase)
- Bilirubin (total and direct bilirubin recommended to distinguish Gilbert's syndrome) 111
Clinical Context
Real-world data shows that 3.2% of patients develop drug-induced liver injury (DILI), typically within two weeks of therapy initiation 3. Post-marketing surveillance in Japan (5,717 patients) reported hepatic function abnormalities in 14.4% and liver disorders in 7.8% of patients 4. Importantly, cases of severe liver injury with fatal outcomes have been reported in the postmarketing period 1, making vigilant monitoring essential for patient safety.
The oncology guideline 5 provides a framework for managing elevated liver enzymes, though it's designed for cancer trials. The principles of repeat testing within 2-5 days for new elevations and more intensive monitoring (2-3 times weekly) for significant elevations can inform management decisions when abnormalities are detected.